A practical reference on HGF mimetic: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2025-09-21. Anything still debated is marked as such rather than presented as settled.
The proposed mechanism for dihexa centers on hepatocyte growth factor, or HGF, and its receptor c-Met. HGF signaling is involved in cell growth, survival, and synapse formation. Dihexa has been described as an HGF mimetic or modulator in preclinical literature. Whether it binds c-Met directly, increases HGF availability, or acts through another route remains uncertain. This mechanistic uncertainty is a recurring theme in reviews of the compound, and no single molecular model has been confirmed across independent laboratories.
Research on dihexa has primarily used rodent models and cultured cells. Common endpoints include dendritic spine density, synaptic protein expression, and performance on maze or avoidance tasks. Some studies report improvements in cognitive measures after scopolamine-induced deficits or in aged animals. These findings are interesting but come from a small body of work, and independent laboratories have not consistently replicated all reported effects. Larger, preregistered studies would help clarify which results are robust.
Development of dihexa followed from studies on angiotensin IV analogs and their effects on learning and memory. Researchers sought compounds with improved metabolic stability and brain penetration compared with natural peptides. In preclinical reports, dihexa was associated with changes in synaptic connectivity and performance on spatial tasks. These findings generated interest in its potential as a cognitive research tool. The work remains largely preclinical, and independent replication has been limited.
Regulatory and commercial contexts differ from clinical medicine. Dihexa is not approved as a drug by major agencies, and no published human trials establish its safety or efficacy. It is often sold as a research chemical labeled for laboratory use only. Suppliers may provide certificates of analysis, but purity and identity depend on the specific batch. Legal status varies by country and may treat such compounds as unapproved substances for human consumption.
| Property | Value | Notes |
|---|---|---|
| Primary proposed target | HGF/c-Met signaling | Direct binding not confirmed |
| Research models | Rodent and cell studies | Preclinical only |
| Human clinical data | None published | Safety and efficacy unknown |
| Regulatory status | Unapproved research chemical | Status varies by country |
| Typical research purity | 95% or higher by HPLC | Depends on supplier and batch |
The proposed mechanism of dihexa centers on activation of the hepatocyte growth factor receptor, also called c-Met. Some studies suggest it acts as a mimetic of hepatocyte growth factor, promoting signaling pathways involved in synapse formation. Other work has explored interactions with angiotensin IV pathways, but the exact binding targets remain uncertain. Laboratory findings come mainly from cell cultures and animal models. Whether these mechanisms operate similarly in humans is an open question. Researchers have not established a single, universally accepted mechanism of action.
Identity and purity of dihexa samples are typically assessed with high-performance liquid chromatography and mass spectrometry. These methods can confirm molecular mass and estimate the presence of impurities. However, a certificate of analysis from a supplier is not a guarantee of independent testing. Researchers often require in-house verification before using a peptide in experiments. For solid samples, appearance, solubility, and chromatographic profile provide additional checks. Nuclear magnetic resonance may be used for structural confirmation when available.
Dihexa is commonly handled as a lyophilized powder in laboratory settings. Storage at -20 °C in a desiccated, light-protected container is typical for peptides. Repeated freeze-thaw cycles can degrade the material, so aliquoting is often recommended. Aqueous solutions may be less stable than organic stocks and should be prepared fresh when possible. Personnel should follow institutional safety procedures and avoid uncontrolled exposure. Because human effects are not well characterized, handling precautions are prudent.
Development of dihexa has been linked to academic research on synaptogenesis, the formation of new synapses. Preclinical studies in rodents have examined its effects on learning and memory tasks. These studies are often cited in discussions about cognitive enhancement, but they do not establish safety or efficacy in humans. The compound's patent and commercial history is limited, and it is not widely available through pharmaceutical channels. Most information comes from animal models and in vitro experiments. Researchers continue to explore its basic biology rather than clinical applications.
Dihexa is not approved for human use in the United States or the European Union. It is commonly sold as a research chemical, a category that may not require the same regulatory review as medicines. Buyers should note that product labels may lack independent verification of identity or purity. The legal status can vary by country, and importation may be restricted. Reliable information about sourcing and quality is often scarce. Scientific publications typically use synthesized material from laboratories rather than commercial consumer products.
Dihexa is a synthetic peptide studied in laboratory research. It is often described as an angiotensin IV analog or a hepatocyte growth factor mimetic. The compound emerged from investigations into angiotensin IV and its effects on neural pathways. It is not an approved medication, and controlled human trials are lacking. In literature and online forums, it is discussed mainly as a research chemical. Its chemical name appears as N-hexanoic-Tyr-Ile-(6-aminohexanoic amide) in some sources.
More sanctions were eased on 13 February, with the issue of two licenses allowing international companies to operate oil and gas projects in Venezuela and to negotiate contracts. Payments go to a US-controlled foreign government deposit fund. US energy secretary that visited the Venezuela in February, said that oil sales have hit $1 billion since January and would hit another $5 billion in months. The US Treasury Department indicated that companies working of Venezuelan oil trade have to pay local taxes, permits and fees to the government of Venezuela, while royalties and federal taxes must be paid into a fund managed by the United States. During the 2026 State of the Union Address, Trump announced that the US "just received from our new friend and partner, Venezuela, more than 80 million barrels of oil." According to the Reuters in February, the Venezuelan oil ministry cancelled 19 contracts with private companies on oil and gas in Venezuela signed under the government of Nicolás Maduro. Venezuelan and US administrations are reviewing the credentials of the companies that signed them. In March, the United States issued a license to authorize the trade of Venezuelan gold and allow deals with Minarven, Venezuela's state-owned gold mining company. On 28 August 2026, President Donald Trump announced that the United States had reached an oil agreement with Venezuela's interim government, led by Delcy Rodríguez. Trump stated on his social media platform that the agreement would give the United States majority control over 65 billion barrels of proven oil reserves in Venezuela.
==== McLean v. Arkansas ==== In 1981, Kenyon was recruited to be an expert witness for the creationist side in the McLean v. Arkansas case that tested the constitutionality of Arkansas' Equal Time Legislation that mandated equal time for "creation science" and "evolution science". Kenyon flew to Arkansas to be deposed and testify during the trial. However, apparently under the influence of creationist attorney Wendell Bird (who was displeased with the defense of the creationist position by the Arkansas attorney general Steve Clark), Kenyon left town just before he was to testify:
Sertraline has also been found to have high affinity for the CNS σ1 receptors. A role of the σ1 site in the pharmacological action of sertraline may exist, but the significance of sertraline affinity for σ1 receptors remains unclear.
Valuable, temperature-sensitive, or hazardous cargo often require the utmost in system reliability. This type of reliability can only be achieved through the installation of a redundant refrigeration system. A redundant refrigeration system consists of integrated primary and back-up refrigeration units. If the primary unit malfunctions, the secondary unit automatically starts. To provide reliable power to the refrigeration units, these containers are often fitted with one or more diesel generator sets. Containers fitted with these systems may be required for transporting certain dangerous goods in order to comply with the International Maritime Organization’s regulations.
Sources: en.wikipedia.org
The internal examination evaluates the condition of the nasal septum, the internal and external nasal valves, the turbinates, and the nasal lining, paying special attention to the structure and the form of the nasal dorsum and the tip of the nose. Furthermore, when warranted, specific tests—the mirror test, vasoconstriction examinations, and the Cottle maneuver—are included to the pre-operative evaluation of the prospective rhinoplasty patient. Established by Maurice H. Cottle (1898–1981), the Cottle maneuver is a principal diagnostic technique for detecting an internal nasal-valve disorder; whilst the patient gently inspires, the surgeon laterally pulls the patient's cheek, thereby simulating the widening of the cross-sectional area of the corresponding internal nasal valve. If the maneuver notably facilitates the patient's inspiration, that result is a positive Cottle sign—which generally indicates an airflow-correction to be surgically effected with an installed spreader-graft. Said correction will improve the internal angle of the nasal valve and thus allow unobstructed breathing. Nonetheless, the Cottle maneuver occasionally yields a false-positive Cottle sign, usually observed in the patient affected by alar collapse, and in the patient with a scarred nasal-valve region.
At the end of the month, it opened a unit in Seoul (owned by 2F Enterprises) and one in Brunei (owned by a subfranchise of A&W Singapore). As of June 1998, A&W only had two restaurants in Mexico. The Cairo branch opened on August 1, 1998, under local franchise American Egyptian Foreign Investments, with Egypt becoming the seventeenth country outside of the United States to open a location. The first co-branded A&W restaurant, tied with Mexican food chain Amigos, opened in Lincoln in 1997. There were plans to increase the amount of co-branded locations across Nebraska by four in the second half of 1998. The goal of the co-branded restaurant was to allure more customers who did not prefer Mexican food. On March 16, 1999, it announced the opening of a restaurant in Dhaka with franchisee Global Supplies Limited due in September that year, with four more planned. The restaurant in Lodi took part in a world record for the largest root beer float of 2562.5 gallons on June 19, 1999, the eve of the eightieth anniversary of the chain. That same year, the chain attempted to enter the Korean market by finding local partners, aiming to grow in the Korean market in the first half of 2000. The plan was ultimately shelved. A&W merged with Long John Silver's to form Yorkshire Global Restaurants based in Lexington, Kentucky in March 1999. Kevin Bazner was promoted president of the chain in July. In 2000, Yorkshire agreed to test multi-branded locations with Tricon Global Restaurants. A grocery location opened in February that year in Idaho.
A press release by the online dating app Tinder showed that the age group 18 to 24 became the majority of users on their platform in 2019. The company boasted 7.86 million users in the United States that year. Nevertheless, even though smartphone applications such as Tinder allow for easy hook-ups and one-night stands, Millennials and Generation Z are quite serious and cautious when it comes to long-term romantic relationships. Unlike generations past, who married earlier and after shorter periods of courtship, Generation Z generally prefers to take things slowly. Generation Z, especially women, is also more likely to have been friends with a romantic partner before dating. Daniel Cox of Five Thirty Eight explains, "This suggests a significant push back [among young Americans] against online dating as a way to meet partners." Most members of this cohort prefer monogamy. However, a significant number is choosing to remain single, because they do not want to be in a relationship, are facing trouble meeting the right people, or have other priorities at present, such as (higher) education or careers. Data from the 2019 General Social Survey revealed that 51% of Americans aged 18 to 24 had no steady partner, higher than other cohorts. Moreover, this number has grown in recent years. Men below the age of 30 are much more likely to be single than women in the same age group.
Sources: en.wikipedia.org
Dihexa has been proposed to act through HGF and c-Met signaling. This pathway is linked to synapse formation and cellular growth. Direct binding and the precise molecular step remain uncertain.
No published human clinical trials are available for dihexa. Its safety and effectiveness in people are therefore unknown. Most available evidence comes from animal and cell studies.
Preclinical studies often measure dendritic spine density and synaptic protein levels. Behavioral tests include maze learning and avoidance tasks. These endpoints are indirect and do not establish clinical benefit.
Dihexa is a synthetic peptidomimetic related to angiotensin IV. It is studied in preclinical research for effects on synaptic signaling and cognition. It is not an approved medication.